SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

Abstract Background In the last decade, several tyrosine kinase inhibitors (TKIs), which disrupt pathways involved in the proliferation and tumorigenesis of thyroid cancer, have been extensively studied. Two different TKIs, lenvatinib and sorafenib, were recently approved by both the US FDA and Euro...

Full description

Bibliographic Details
Main Authors: Soo Young Kim, Seok-Mo Kim, Ho-Jin Chang, Bup-Woo Kim, Yong Sang Lee, Cheong Soo Park, Ki Cheong Park, Hang-Seok Chang
Format: Article
Language:English
Published: BMC 2018-10-01
Series:BMC Cancer
Subjects:
Papillary thyroid cancer
Lenvatinib
Sorafenib
EMT
FGF signaling
TKI
Online Access:http://link.springer.com/article/10.1186/s12885-018-4854-z

Internet

http://link.springer.com/article/10.1186/s12885-018-4854-z

Similar Items